http://120.24.161.253:5617/index.php?action=history&feed=atom&title=%E5%AD%90%E5%AE%AB%E5%86%85%E8%86%9C%E5%BC%82%E4%BD%8D%E7%97%87-%E5%AE%9E%E9%AA%8C%E5%AE%A4%E6%A3%80%E6%9F%A5-CA19-9 2026-04-26T03:55:21Z 本wiki的该页面的版本历史 MediaWiki 1.30.0 http://120.24.161.253:5617/index.php?title=%E5%AD%90%E5%AE%AB%E5%86%85%E8%86%9C%E5%BC%82%E4%BD%8D%E7%97%87-%E5%AE%9E%E9%AA%8C%E5%AE%A4%E6%A3%80%E6%9F%A5-CA19-9&diff=1689174&oldid=prev 2024-07-06T14:00:00Z

<p>修改1</p> <table class="diff diff-contentalign-left" data-mw="interface"> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="1" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="1" style="background-color: white; color:black; text-align: center;">2024年7月6日 (六) 14:00的版本</td> </tr><tr><td colspan="2" style="text-align: center;" lang="zh-CN"><div class="mw-diff-empty">（没有差异）</div> </td></tr></table>

Admin http://120.24.161.253:5617/index.php?title=%E5%AD%90%E5%AE%AB%E5%86%85%E8%86%9C%E5%BC%82%E4%BD%8D%E7%97%87-%E5%AE%9E%E9%AA%8C%E5%AE%A4%E6%A3%80%E6%9F%A5-CA19-9&diff=1689175&oldid=prev 2024-07-06T12:46:21Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="2" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: white; color:black; text-align: center;">2024年7月6日 (六) 12:46的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l13" >第13行：</td> <td colspan="2" class="diff-lineno">第13行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===CA125、CA19-9联合检测在卵巢上皮癌和子宫内膜异位症中的临床价值（中华医学会文献）===</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===CA125、CA19-9联合检测在卵巢上皮癌和子宫内膜异位症中的临床价值（中华医学会文献）===</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>结果 卵巢上皮癌组患者血清CA125和[[CA19-9]]水平明显高于[[子宫内膜异位症]]组和对照组(P<del class="diffchange diffchange-inline">&lt;</del>0.05;P<del class="diffchange diffchange-inline">&lt;</del>0.01);[[子宫内膜异位症]]组患者血清CA125和[[CA19-9]]水平明显高于对照组(P<del class="diffchange diffchange-inline">&lt;</del>0.05);血清CA125与[[CA19-9]]联合测定较单项检测敏感度高</div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>结果 卵巢上皮癌组患者血清CA125和[[CA19-9]]水平明显高于[[子宫内膜异位症]]组和对照组(P<ins class="diffchange diffchange-inline">&amp;amp;lt;</ins>0.05;P<ins class="diffchange diffchange-inline">&amp;amp;lt;</ins>0.01);[[子宫内膜异位症]]组患者血清CA125和[[CA19-9]]水平明显高于对照组(P<ins class="diffchange diffchange-inline">&amp;amp;lt;</ins>0.05);血清CA125与[[CA19-9]]联合测定较单项检测敏感度高</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===子宫内膜异位症患者治疗前后血浆ET-1、血清TNF-α和CA19-9检测的临床意义（中华医学会文献）===</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===子宫内膜异位症患者治疗前后血浆ET-1、血清TNF-α和CA19-9检测的临床意义（中华医学会文献）===</div></td></tr> </table>

KGadmin http://120.24.161.253:5617/index.php?title=%E5%AD%90%E5%AE%AB%E5%86%85%E8%86%9C%E5%BC%82%E4%BD%8D%E7%97%87-%E5%AE%9E%E9%AA%8C%E5%AE%A4%E6%A3%80%E6%9F%A5-CA19-9&diff=662041&oldid=prev 2021-11-23T03:51:08Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="1" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="1" style="background-color: white; color:black; text-align: center;">2021年11月23日 (二) 03:51的版本</td> </tr><tr><td colspan="2" style="text-align: center;" lang="zh-CN"><div class="mw-diff-empty">（没有差异）</div> </td></tr></table>

Admin http://120.24.161.253:5617/index.php?title=%E5%AD%90%E5%AE%AB%E5%86%85%E8%86%9C%E5%BC%82%E4%BD%8D%E7%97%87-%E5%AE%9E%E9%AA%8C%E5%AE%A4%E6%A3%80%E6%9F%A5-CA19-9&diff=662033&oldid=prev 2021-10-19T13:56:59Z

<p>修改1</p> <p><b>新页面</b></p><div>主实体：[[子宫内膜异位症]]，关系：[[实验室检查]] ，尾实体：[[CA19-9]]<br /> <br /> 实体ID:''2267767''<br /> ==关系介绍==<br /> 待补充<br /> <br /> ==来源==<br /> ===子宫内膜异位症患者血清CA125及CA19-9联合测定的临床评价（中华医学会文献）===<br /> [[子宫内膜异位症]]患者血清CA125及[[CA19-9]]联合测定的临床评价<br /> <br /> ===子宫内膜异位症生化标记物的临床意义（中华医学会文献）===<br /> [[子宫内膜异位症]]患者体内有许多生化分子的表达发生变化,其与[[子宫内膜异位症]]的发生、发展有关,如CA-125、[[CA19-9]]、抗子宫内膜抗体等,目前已经是内异症诊断的重要辅助手段.<br /> <br /> ===CA125、CA19-9联合检测在卵巢上皮癌和子宫内膜异位症中的临床价值（中华医学会文献）===<br /> 结果 卵巢上皮癌组患者血清CA125和[[CA19-9]]水平明显高于[[子宫内膜异位症]]组和对照组(P&lt;0.05;P&lt;0.01);[[子宫内膜异位症]]组患者血清CA125和[[CA19-9]]水平明显高于对照组(P&lt;0.05);血清CA125与[[CA19-9]]联合测定较单项检测敏感度高<br /> <br /> ===子宫内膜异位症患者治疗前后血浆ET-1、血清TNF-α和CA19-9检测的临床意义（中华医学会文献）===<br /> [[子宫内膜异位症]]患者治疗前后血浆ET-1、血清TNF-α和[[CA19-9]]检测的临床意义<br /> <br /> ===血清CA125和CA19-9水平对子宫内膜异位症诊断价值的探讨（中华医学会文献）===<br /> 2.22%和(20.26±8.25)U/ml、10.00%;[[子宫内膜异位症]]患者血清CA125和[[CA19-9]]检测值显著高于对照组(P＜0.001);[[子宫内膜异位症]]患者血清CA125和[[CA19-9]]阳性率显著高于对照组(P＜0.001);[[子宫内膜异位症]]血清CA1</div>

Admin